Roivant Sciences Inc (NASDAQ:ROIV) Share Price Down 2.3%
Roivant Sciences Ltd (NASDAQ: ROIV – Get a rating) the stock price fell 2.3% in Tuesday’s session. The company traded as low as $4.21 and last traded at $4.28. Around 4,355 shares were traded at midday, down 100% from the average daily volume of 1,340,506 shares. The stock had previously closed at $4.38.
ROIV has been the subject of a number of research reports. SVB Leerink launched coverage on Roivant Sciences in a report on Monday, May 23. They issued an “outperform” rating and a $6.00 price target on the stock. Cantor Fitzgerald launched coverage on Roivant Sciences in a report on Friday, April 29. They issued an “overweight” rating and a price target of $15.00 on the stock. Finally, Goldman Sachs Group cut its price target on Roivant Sciences from $15.00 to $12.00 and set a “buy” rating on the stock in a Tuesday, May 24 report. Eight analysts rated the stock with a buy rating. According to data from MarketBeat.com, the stock has a consensus buy rating and an average price target of $11.86.
The company has a fifty-day simple moving average of $3.84 and a 200-day simple moving average of $5.58. The company has a current ratio of 14.23, a quick ratio of 14.23 and a debt ratio of 0.09.
In other Roivant Sciences news, COO Eric Venker sold 80,045 shares of Roivant Sciences in a trade on Friday, March 25. The stock was sold at an average price of $5.06, for a total transaction of $405,027.70. The sale was disclosed in an SEC filing, available at this hyperlink. Additionally, CEO Matthew Gline sold 139,791 shares of Roivant Sciences in a trade on Friday, May 20. The shares were sold at an average price of $3.70, for a total value of $517,226.70. Following the sale, the CEO now directly owns 1,264,657 shares of the company, valued at approximately $4,679,230.90. Disclosure of this sale can be found here. Last quarter, insiders sold 480,878 shares of the company valued at $2,011,421.
Several institutional investors and hedge funds have recently bought and sold shares of ROIV. Citigroup Inc. increased its stake in shares of Roivant Sciences by 1,803.6% in the 1st quarter. Citigroup Inc. now owns 5,749 shares of the company worth $28,000 after buying 5,447 additional shares in the last quarter. Royal Bank of Canada increased its position in shares of Roivant Sciences by 60,550.0% during the first quarter. Royal Bank of Canada now owns 6,065 shares of the company worth $30,000 after purchasing an additional 6,055 shares during the period. Hsbc Holdings PLC increased its position in shares of Roivant Sciences by 25.4% during the first quarter. Hsbc Holdings PLC now owns 14,684 shares in the company worth $71,000 after purchasing 2,978 additional shares during the period. Goldman Sachs Group Inc. acquired a new stake in shares of Roivant Sciences during the first quarter at a value of $100,000. Finally, Susquehanna International Group LLP bought a new position in shares of Roivant Sciences during the fourth quarter at a value of $108,000. 61.49% of the shares are currently held by institutional investors.
Roivant Sciences company profile (NASDAQ: ROIV)
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops drugs. The Company is developing product candidates for the treatment of various therapeutics, including solid tumors, sickle cell disease, hypophosphatasia, oncological malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis severe, autoimmune warm hemolytic anemia, thyroid eye disease, sarcoidosis, and Staphylococcus aureus bacteremia.
Get news and reviews for Roivant Sciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst assessments for Roivant Sciences and related companies with MarketBeat.com’s free daily email newsletter.